8 insiders reported 46 Form 4 transactions for Intra-Cellular Therapies, Inc. (ITCI) over the past 18 months (most recent 2025-04-02). Recent activity: Salas Eduardo Rene (Director) Sell 1,567 shares, RIGGS RORY B (Director) Sell 131,512 shares, MARCUS JOEL S (Director) Sell 48,238 shares, MARCUS JOEL S (Director) Sell 10,000 shares, Mates Sharon (Chairman and CEO) Sell 945,235 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-02 | Salas Eduardo Rene | Director | Sell | 1,567 | $206,844 |
| 2025-04-02 | RIGGS RORY B | Director | Sell | 131,512 | $17.4M |
| 2025-04-02 | MARCUS JOEL S | Director | Sell | 48,238 | $6.4M |
| 2025-04-02 | MARCUS JOEL S | Director | Sell | 10,000 | $1.3M |
| 2025-04-02 | Mates Sharon | Chairman and CEO | Sell | 945,235 | $124.8M |
| 2025-04-02 | Mates Sharon | Chairman and CEO | Sell | 190,000 | $25.1M |
| 2025-04-02 | VAN NOSTRAND ROBERT L | Director | Sell | 11,340 | $1.5M |
| 2025-04-02 | Halstead Michael | President | Sell | 21,307 | $2.8M |
| 2025-04-02 | Neumann Mark | EVP, Chief Commercial Officer | Sell | 52,811 | $7.0M |
| 2025-04-02 | Durgam Suresh K. | EVP, Chief Medical Officer | Sell | 42,913 | $5.7M |
| 2025-03-31 | Mates Sharon | Chairman and CEO | Sell | 190,000 | $0 |
| 2025-03-31 | Mates Sharon | Chairman and CEO | Buy | 190,000 | $0 |
| 2025-03-10 | Halstead Michael | President | Buy | 13,133 | $0 |
| 2025-03-10 | Neumann Mark | EVP, Chief Commercial Officer | Buy | 13,133 | $0 |
| 2025-03-10 | Neumann Mark | EVP, Chief Commercial Officer | Sell | 5,572 | $730,991 |
| 2025-03-10 | Neumann Mark | EVP, Chief Commercial Officer | Sell | 3,116 | $408,944 |
| 2025-03-10 | Durgam Suresh K. | EVP, Chief Medical Officer | Buy | 13,133 | $0 |
| 2025-03-10 | Durgam Suresh K. | EVP, Chief Medical Officer | Sell | 5,572 | $730,991 |
| 2025-03-10 | Durgam Suresh K. | EVP, Chief Medical Officer | Buy | 7,345 | $0 |
| 2025-03-10 | Durgam Suresh K. | EVP, Chief Medical Officer | Sell | 3,116 | $408,944 |
| 2025-03-10 | Mates Sharon | Chairman and CEO | Buy | 40,712 | $0 |
| 2025-03-10 | Mates Sharon | Chairman and CEO | Sell | 19,848 | $2.6M |
| 2025-03-10 | Mates Sharon | Chairman and CEO | Buy | 20,566 | $0 |
| 2025-03-10 | Mates Sharon | Chairman and CEO | Sell | 10,129 | $1.3M |
| 2025-03-10 | Neumann Mark | EVP, Chief Commercial Officer | Buy | 7,345 | $0 |
Source: SEC Form 4 filings · as of 2025-04-02
